Corroborated event · 2 outlets
Alphabet's Isomorphic Labs closed a $5 billion investment round to accelerate AI drug discovery.
AI brief
Isomorphic Labs raised $5 billion, six months after a $2.1 billion round. The Alphabet-owned AI drug discovery company, led by Demis Hassabis, plans to use the funds to move its drug pipeline toward clinical trials and has no approved drugs yet.
Why it matters: It is a large funding round for an AI drug discovery company that has yet to bring a drug to approval, and the money is aimed at reaching clinical trials.
Written by AI from The Decoder's published text.
Background
From our own funding, model and news trackers, not from the source.
Isomorphic Labs
- Latest funding
- Series C · $5B · 17 Nov 2026
- Last 30 days
- 3 news stories
More coverage of this story (1)
Isomorphic Labs raises $5 billion in funding
Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials
TechCrunch AI · 17 Nov 2026, 14:50
Primary source
“Isomorphic Labs has raised $5 billion, just six months after a $2.1 billion round. Alphabet's AI drug discovery company, led by Demis Hassabis, plans to use the funding to push its drug pipeline toward clinical trials. The company has no approved drugs yet.”
Reporting from a publisher outside the organisation being covered.
Read original story ↗